
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is an attractive investment opportunity with a strong pipeline of clinical-stage vaccines in both oncology and infectious diseases, backed by its proprietary AI-Immunology platform. The company has a well-established executive team, led by a CEO with a track record of successful partnerships. With an impressive 86% immunogenic neoantigen rate and potential partnerships in the near future, we maintain a positive outlook on Evaxion's stock and have a 12-month price target of $16.00 per share. However, risks such as competition and regulatory concerns could impact the company's success.
Bears say
Evaxion is utilizing their proprietary AI-Immunology platform to develop novel vaccines for both cancer and infectious diseases with a high unmet medical need. With positive preclinical data for their lead candidate, EVX-04, the company is transitioning towards a scalable and off-the-shelf alternative to personalized cancer vaccines, addressing scalability and time-to-treatment concerns. However, with an estimated IND filing in the second half of 2026, there may be a longer wait time for potential revenue and profitability from their pipeline.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares